This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Zelenetz AD , Gordon LI , Abramson JS , Advani RH , Bartlett NL , Caimi PF , Chang JE , Chavez JC , Christian B , Fayad LE , Glenn MJ , Habermann TM , Lee Harris N , Hernandez-Ilizaliturri F , Kaminski MS , Kelsey CR , Khan N , Krivacic S , LaCasce AS , Mehta A , Nademanee A , Rabinovitch R , Reddy N , Reid E , Roberts KB , Smith SD , Snyder ED , Swinnen LJ , Vose JM , Dwyer MA , Sundar H
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
J Natl Compr Canc Netw. 2019 Jun 1;17(6) :650-661
PMID: 31200358 URL: https://www.ncbi.nlm.nih.gov/pubmed/31200358
AbstractDiffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL.
NotesZelenetz, Andrew D Gordon, Leo I Abramson, Jeremy S Advani, Ranjana H Bartlett, Nancy L Caimi, Paolo F Chang, Julie E Chavez, Julio C Christian, Beth Fayad, Luis E Glenn, Martha J Habermann, Thomas M Lee Harris, Nancy Hernandez-Ilizaliturri, Francisco Kaminski, Mark S Kelsey, Christopher R Khan, Nadia Krivacic, Susan LaCasce, Ann S Mehta, Amitkumar Nademanee, Auayporn Rabinovitch, Rachel Reddy, Nishitha Reid, Erin Roberts, Kenneth B Smith, Stephen D Snyder, Erin D Swinnen, Lode J Vose, Julie M Dwyer, Mary A Sundar, Hema eng J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.